Daiichi Sankyo, Merck
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study,
Astra, Daiichi Drop on Mixed Lung Cancer Drug Trial Result
Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with AstraZeneca showed mixed results in a phase 3 trial.
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC),
FierceBiotech5h
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
MM&M2d
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
FiercePharma3d
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
FierceBiotech6d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
pharmaphorum4d
Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
FiercePharma3d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
ジャパンタイムズ6d
Daiichi wants to go it alone in search for targeted cancer drugs
The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...
NHS England to offer Daiichi Sankyo’s quizartinib for AML
The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.